| Obesity
Zepbound vs Wegovy
Side-by-side clinical, coverage, and cost comparison for obesity.Deep comparison between: Zepbound vs Wegovy with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsWegovy has a higher rate of injection site reactions vs Zepbound based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Wegovy but not Zepbound, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Zepbound
Wegovy
At A Glance
SC injection
Once weekly
GIP/GLP-1 receptor agonist
SC injection
Once weekly
GLP-1 receptor agonist
Indications
- Obesity
- Sleep Apnea, Obstructive
- Obesity
- Nonalcoholic Steatohepatitis
Dosing
Obesity Starting dose 2.5 mg SC once weekly for 4 weeks, escalating in 2.5 mg increments every 4 weeks; maintenance 5 mg, 10 mg, or 15 mg SC once weekly.
Sleep Apnea, Obstructive Starting dose 2.5 mg SC once weekly for 4 weeks, escalating in 2.5 mg increments every 4 weeks; maintenance 10 mg or 15 mg SC once weekly.
Obesity Adults: maintenance 2.4 mg (or 1.7 mg) SC injection once weekly after escalation from 0.25 mg, or 25 mg tablet orally once daily after escalation from 1.5 mg; pediatric patients aged 12 years and older: 2.4 mg (or 1.7 mg) SC injection once weekly.
Nonalcoholic Steatohepatitis 2.4 mg SC injection once weekly (maintenance) after escalation from 0.25 mg; may reduce to 1.7 mg once weekly if 2.4 mg not tolerated.
Cardiovascular risk reduction Maintenance 2.4 mg (or 1.7 mg) SC injection once weekly after escalation from 0.25 mg, or 25 mg tablet orally once daily after escalation from 1.5 mg.
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Known serious hypersensitivity to tirzepatide or any excipient in ZEPBOUND
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Prior serious hypersensitivity reaction to semaglutide or to any excipient in WEGOVY injection or WEGOVY tablet
Adverse Reactions
Most common (>=2%) Nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, gastroesophageal reflux disease, flatulence, abdominal distension, dizziness
Serious Risk of thyroid C-cell tumors, severe gastrointestinal reactions, acute kidney injury, acute gallbladder disease, acute pancreatitis, hypersensitivity reactions including anaphylaxis and angioedema, hypoglycemia, diabetic retinopathy complications, pulmonary aspiration
Postmarketing Acute pancreatitis, hemorrhagic and necrotizing pancreatitis, ileus, intestinal obstruction, severe constipation including fecal impaction, anaphylaxis, angioedema, pulmonary aspiration, acute renal failure or worsening of chronic renal failure
Most common (>=2%) Nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, flatulence, gastroenteritis, gastroesophageal reflux disease, gastritis, hair loss, dysesthesia
Serious Risk of thyroid C-cell tumors, acute pancreatitis, acute gallbladder disease, hypoglycemia, acute kidney injury, severe gastrointestinal reactions, hypersensitivity reactions including anaphylaxis and angioedema, diabetic retinopathy complications, heart rate increase, pulmonary aspiration during anesthesia
Postmarketing Acute pancreatitis and necrotizing pancreatitis, ileus, intestinal obstruction, severe constipation including fecal impaction, anaphylaxis, angioedema, rash, urticaria, pulmonary aspiration, acute kidney injury
Pharmacology
Tirzepatide is a dual GIP receptor and GLP-1 receptor agonist that selectively binds and activates both receptors, reducing body weight by decreasing caloric intake and affecting appetite regulation, stimulating glucose-dependent insulin secretion, reducing glucagon secretion, and delaying gastric emptying.
Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to human GLP-1 that selectively binds and activates the GLP-1 receptor, regulating appetite and caloric intake, stimulating glucose-dependent insulin secretion, reducing glucagon secretion, and delaying gastric emptying.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Zepbound
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
Wegovy
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Zepbound
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (1/8)
Wegovy
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Zepbound
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (0/3)
Wegovy
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$25/fillfill
Zepbound Savings Card - Covered benefitCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
$349/momo
Wegovy Self-Pay Program - InjectableCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ZepboundView full Zepbound profile
WegovyView full Wegovy profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.